Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chart: Shared Strengths: The Merck And Schering Pipelines

Executive Summary

For a company that takes pride in the strength of its R&D organization, Merck's late-stage pipeline has needed an infusion for some time. High-risk products such as Cordaptive and the CETP inhibitor anaceptrapib have suffered clinical setbacks while drugs like the CB-1 antagonist taranabant have been outright failures, leaving a thin Phase III pipeline ("The Pink Sheet" Oct. 6, 2008, p. 22). The proposed acquisition of Schering-Plough brings Merck some of what it needs - a range of late-stage opportunities that round out the Whitehouse, N.J.-based drugmaker's existing portfolio, strengthening its positions in neuroscience and respiratory drugs. Thanks to Schering, the company will have three pending NME products at FDA this year, where it previously had none. The deal also gives Merck potential blockbuster drugs if TRA and bocepravir deliver in clinical trials. Much of the credit for Schering's pipeline goes to CEO Fred Hassan, who has focused on rebuilding that pharma's pipeline via licensing and acquisition. In particular, the 2007 takeover of Organon BioSciences, which added central nervous system and women's health assets, was critical to Merck's desire to purchase the company. Organon assets now comprise three-quarters of Schering's pipeline. Here's a closer look at the combined Merck-Schering pipeline, with an emphasis on novel products or combinations in mid- to late-stage development.

You may also be interested in...

Merck/Schering Merger Brings A Partial Solution For Sales & Marketing

When Merck and Schering Plough executives promoted their proposed $41 billion merger March 9, they forecasted compounded annual earnings growth in the high single digits over each of the next several years. But they paid scant attention to top-line growth

Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline

Merck's widely expected decision to drop its Phase III obesity candidate taranabant places further doubt on the tainted cannabinoid-1 receptor antagonist class, but it also places doubt on Merck's near-term pipeline

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts